Search
NovaBay Pharmaceuticals Inc
NBYAdd to Watchlist
1.950USD
0.0000.00%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
43.67MMarket Cap
LossP/E TTM
More Details of NovaBay Pharmaceuticals Inc Company
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
NovaBay Pharmaceuticals Inc Info
Ticker SymbolNBY
Company nameNovaBay Pharmaceuticals Inc
IPO dateOct 26, 2007
CEOKazley (Michael John)
Number of employees14
Security typeOrdinary Share
Fiscal year-endOct 26
Address2000 Powell St Ste 1150
CityEMERYVILLE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code94608-1804
Phone15108998800
Websitehttps://novabay.com/
Ticker SymbolNBY
IPO dateOct 26, 2007
CEOKazley (Michael John)
Company Executives of NovaBay Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
172.00
-10.47%
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
6.00
+16.67%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Mr. Michael Kazley
Mr. Michael Kazley
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
172.00
-10.47%
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
6.00
+16.67%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Revenue Breakdown
FY2025Q3
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
521.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
R01 Fund LP
42.67%
Framework Ventures Management LLC
42.67%
Lazar (David Elliot)
4.80%
BlackRock Institutional Trust Company, N.A.
1.38%
Vanguard Capital Management, LLC
1.02%
Other
7.46%
Shareholders
Shareholders
Proportion
R01 Fund LP
42.67%
Framework Ventures Management LLC
42.67%
Lazar (David Elliot)
4.80%
BlackRock Institutional Trust Company, N.A.
1.38%
Vanguard Capital Management, LLC
1.02%
Other
7.46%
Shareholder Types
Shareholders
Proportion
Corporation
85.34%
Individual Investor
4.80%
Investment Advisor
3.05%
Investment Advisor/Hedge Fund
1.40%
Hedge Fund
0.81%
Research Firm
0.15%
Pension Fund
0.02%
Other
4.43%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
47
1.80M
6.77%
+1.46M
2025Q4
41
3.14M
2.49%
+1.61M
2025Q3
38
1.37M
22.81%
-82.54K
2025Q2
43
1.43M
24.52%
+210.59K
2025Q1
42
1.34M
22.96%
+376.59K
2024Q4
40
546.91K
11.19%
+390.20K
2024Q3
42
126.44K
2.60%
+79.02K
2024Q2
44
12.01K
0.89%
-33.08K
2024Q1
44
12.73K
1.48%
-22.10K
2023Q4
45
34.29K
18.48%
+25.73K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
R01 Fund LP
11.36M
42.67%
--
--
Feb 09, 2026
Framework Ventures Management LLC
11.36M
42.67%
--
--
Feb 09, 2026
Lazar (David Elliot)
1.28M
4.8%
--
--
Jan 29, 2026
BlackRock Institutional Trust Company, N.A.
366.15K
1.38%
+366.15K
--
Dec 31, 2025
Geode Capital Management, L.L.C.
251.54K
0.94%
+241.20K
+2331.76%
Dec 31, 2025
Poplar Point Capital Management LLC
204.06K
0.77%
--
--
Nov 04, 2025
Jane Street Capital, L.L.C.
14.01K
0.05%
+14.01K
--
Dec 31, 2025
State Street Investment Management (US)
62.74K
0.24%
+56.88K
+970.48%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Feb 12, 2026
Merger
5→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Date
Ex-dividend Date
Type
Ratio
Feb 12, 2026
Merger
5→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
